AT268323B - Process for the preparation of new 3,1-benzothiazine derivatives and their salts - Google Patents
Process for the preparation of new 3,1-benzothiazine derivatives and their saltsInfo
- Publication number
- AT268323B AT268323B AT625267A AT625267A AT268323B AT 268323 B AT268323 B AT 268323B AT 625267 A AT625267 A AT 625267A AT 625267 A AT625267 A AT 625267A AT 268323 B AT268323 B AT 268323B
- Authority
- AT
- Austria
- Prior art keywords
- acid
- salts
- benzoxazine
- methyl
- compounds
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 13
- 150000003839 salts Chemical class 0.000 title claims description 10
- 238000002360 preparation method Methods 0.000 title description 4
- CURPPPMZYPWREO-UHFFFAOYSA-N 2h-3,1-benzothiazine Chemical class C1=CC=CC2=NCSC=C21 CURPPPMZYPWREO-UHFFFAOYSA-N 0.000 title description 3
- 239000002253 acid Substances 0.000 claims description 9
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 150000007524 organic acids Chemical class 0.000 claims description 5
- 235000005985 organic acids Nutrition 0.000 claims description 5
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 5
- 150000007514 bases Chemical class 0.000 claims description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 4
- CYQAYERJWZKYML-UHFFFAOYSA-N phosphorus pentasulfide Chemical compound S1P(S2)(=S)SP3(=S)SP1(=S)SP2(=S)S3 CYQAYERJWZKYML-UHFFFAOYSA-N 0.000 claims description 4
- RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical compound S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 239000007795 chemical reaction product Substances 0.000 claims description 3
- 229910000037 hydrogen sulfide Inorganic materials 0.000 claims description 3
- 239000007858 starting material Substances 0.000 claims description 3
- 229910052945 inorganic sulfide Inorganic materials 0.000 claims description 2
- 230000004048 modification Effects 0.000 claims description 2
- 238000012986 modification Methods 0.000 claims description 2
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 18
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
- 239000000047 product Substances 0.000 description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- -1 benzylimino group Chemical group 0.000 description 6
- 238000002844 melting Methods 0.000 description 6
- 230000008018 melting Effects 0.000 description 6
- 239000003208 petroleum Substances 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 239000013078 crystal Substances 0.000 description 5
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 239000012948 isocyanate Substances 0.000 description 4
- 150000002513 isocyanates Chemical class 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000001816 cooling Methods 0.000 description 3
- 230000003001 depressive effect Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 238000001953 recrystallisation Methods 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- NAWYZLGDGZTAPN-UHFFFAOYSA-N (2-aminophenyl)-phenylmethanol Chemical class NC1=CC=CC=C1C(O)C1=CC=CC=C1 NAWYZLGDGZTAPN-UHFFFAOYSA-N 0.000 description 2
- QPFMBZIOSGYJDE-UHFFFAOYSA-N 1,1,2,2-tetrachloroethane Chemical compound ClC(Cl)C(Cl)Cl QPFMBZIOSGYJDE-UHFFFAOYSA-N 0.000 description 2
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 2
- AZQLKTXJXUFVBC-UHFFFAOYSA-N C(C)NC1=NC2=C(C(O1)C)C=CC=C2 Chemical compound C(C)NC1=NC2=C(C(O1)C)C=CC=C2 AZQLKTXJXUFVBC-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- CIUQDSCDWFSTQR-UHFFFAOYSA-N [C]1=CC=CC=C1 Chemical compound [C]1=CC=CC=C1 CIUQDSCDWFSTQR-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000005840 aryl radicals Chemical class 0.000 description 2
- 239000002585 base Substances 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- MVPPADPHJFYWMZ-UHFFFAOYSA-N chlorobenzene Chemical compound ClC1=CC=CC=C1 MVPPADPHJFYWMZ-UHFFFAOYSA-N 0.000 description 2
- 125000004985 dialkyl amino alkyl group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- QILSFLSDHQAZET-UHFFFAOYSA-N diphenylmethanol Chemical class C=1C=CC=CC=1C(O)C1=CC=CC=C1 QILSFLSDHQAZET-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 150000004820 halides Chemical class 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000008164 mustard oil Substances 0.000 description 2
- ATLXNSGAKLDEIG-UHFFFAOYSA-N n-ethyl-4-methyl-4h-3,1-benzothiazin-2-amine Chemical compound C1=CC=C2C(C)SC(NCC)=NC2=C1 ATLXNSGAKLDEIG-UHFFFAOYSA-N 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- NDVLTYZPCACLMA-UHFFFAOYSA-N silver oxide Chemical compound [O-2].[Ag+].[Ag+] NDVLTYZPCACLMA-UHFFFAOYSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229910052717 sulfur Inorganic materials 0.000 description 2
- 125000004434 sulfur atom Chemical group 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- PAHDPXOLONPKTP-UHFFFAOYSA-N (2-amino-5-chlorophenyl)-phenylmethanol Chemical compound NC1=CC=C(Cl)C=C1C(O)C1=CC=CC=C1 PAHDPXOLONPKTP-UHFFFAOYSA-N 0.000 description 1
- MKJIEFSOBYUXJB-HOCLYGCPSA-N (3S,11bS)-9,10-dimethoxy-3-isobutyl-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a]isoquinolin-2-one Chemical compound C1CN2C[C@H](CC(C)C)C(=O)C[C@H]2C2=C1C=C(OC)C(OC)=C2 MKJIEFSOBYUXJB-HOCLYGCPSA-N 0.000 description 1
- GOJUJUVQIVIZAV-UHFFFAOYSA-N 2-amino-4,6-dichloropyrimidine-5-carbaldehyde Chemical group NC1=NC(Cl)=C(C=O)C(Cl)=N1 GOJUJUVQIVIZAV-UHFFFAOYSA-N 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- VTKUBJVCZMMNMR-UHFFFAOYSA-N 3-isocyanato-n,n-dimethylpropan-1-amine Chemical compound CN(C)CCCN=C=O VTKUBJVCZMMNMR-UHFFFAOYSA-N 0.000 description 1
- VRHRPDVEFVZCPK-UHFFFAOYSA-N 4-ethyl-N-methyl-1,4-dihydro-3,1-benzoxazin-2-imine Chemical compound CNC1=NC2=C(C(O1)CC)C=CC=C2 VRHRPDVEFVZCPK-UHFFFAOYSA-N 0.000 description 1
- FCFDSHDLLOBZRU-UHFFFAOYSA-N 4-phenyl-4H-3,1-benzoxazin-2-amine Chemical compound NC1=NC2=C(C(O1)C1=CC=CC=C1)C=CC=C2 FCFDSHDLLOBZRU-UHFFFAOYSA-N 0.000 description 1
- RKYKDWLNRCUQTO-UHFFFAOYSA-N 5-methyl-4H-3,1-benzoxazin-2-amine Chemical compound NC1=NC2=C(CO1)C(=CC=C2)C RKYKDWLNRCUQTO-UHFFFAOYSA-N 0.000 description 1
- UGNBKUOIMWUPTG-UHFFFAOYSA-N 6-chloro-4-phenyl-4H-3,1-benzoxazin-2-amine Chemical compound NC1=NC2=C(C(O1)C1=CC=CC=C1)C=C(C=C2)Cl UGNBKUOIMWUPTG-UHFFFAOYSA-N 0.000 description 1
- RLGZDOZXCANJJE-UHFFFAOYSA-N 6-chloro-N-ethyl-4-methyl-1,4-dihydro-3,1-benzoxazin-2-imine Chemical compound C1=C(Cl)C=C2C(C)OC(NCC)=NC2=C1 RLGZDOZXCANJJE-UHFFFAOYSA-N 0.000 description 1
- UBTQURXIKQMINI-UHFFFAOYSA-N 6-chloro-N-ethyl-4-phenyl-1,4-dihydro-3,1-benzoxazin-2-imine Chemical compound C(C)NC1=NC2=C(C(O1)C1=CC=CC=C1)C=C(C=C2)Cl UBTQURXIKQMINI-UHFFFAOYSA-N 0.000 description 1
- ZGOWZGZRTGGMMM-UHFFFAOYSA-N 6-chloro-n-ethyl-4-phenyl-4h-3,1-benzothiazin-2-amine Chemical compound S1C(NCC)=NC2=CC=C(Cl)C=C2C1C1=CC=CC=C1 ZGOWZGZRTGGMMM-UHFFFAOYSA-N 0.000 description 1
- DOCAHNNCZFWIIM-UHFFFAOYSA-N 7-chloro-N-ethyl-4-phenyl-1,4-dihydro-3,1-benzoxazin-2-imine Chemical compound C(C)NC1=NC2=C(C(O1)C1=CC=CC=C1)C=CC(=C2)Cl DOCAHNNCZFWIIM-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- GUPUZPJRCLWZRB-UHFFFAOYSA-N C(C1=CC=CC=C1)NC1=NC2=C(C(O1)C1=CC=CC=C1)C=C(C=C2)OC Chemical compound C(C1=CC=CC=C1)NC1=NC2=C(C(O1)C1=CC=CC=C1)C=C(C=C2)OC GUPUZPJRCLWZRB-UHFFFAOYSA-N 0.000 description 1
- CKDWPUIZGOQOOM-UHFFFAOYSA-N Carbamyl chloride Chemical class NC(Cl)=O CKDWPUIZGOQOOM-UHFFFAOYSA-N 0.000 description 1
- 208000009132 Catalepsy Diseases 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- OWIKHYCFFJSOEH-UHFFFAOYSA-N Isocyanic acid Chemical compound N=C=O OWIKHYCFFJSOEH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- OKJIRPAQVSHGFK-UHFFFAOYSA-N N-acetylglycine Chemical compound CC(=O)NCC(O)=O OKJIRPAQVSHGFK-UHFFFAOYSA-N 0.000 description 1
- FULZLIGZKMKICU-UHFFFAOYSA-N N-phenylthiourea Chemical compound NC(=S)NC1=CC=CC=C1 FULZLIGZKMKICU-UHFFFAOYSA-N 0.000 description 1
- BCPFYPNLVGADIG-UHFFFAOYSA-N NC1=C(C(C2=CC=CC=C2)(O)Br)C=CC=C1 Chemical class NC1=C(C(C2=CC=CC=C2)(O)Br)C=CC=C1 BCPFYPNLVGADIG-UHFFFAOYSA-N 0.000 description 1
- 206010029333 Neurosis Diseases 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 240000005578 Rivina humilis Species 0.000 description 1
- 208000032140 Sleepiness Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010047853 Waxy flexibility Diseases 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003342 alkenyl group Chemical group 0.000 description 1
- 125000003545 alkoxy group Chemical group 0.000 description 1
- ZOJBYZNEUISWFT-UHFFFAOYSA-N allyl isothiocyanate Chemical compound C=CCN=C=S ZOJBYZNEUISWFT-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-N anhydrous cyanic acid Natural products OC#N XLJMAIOERFSOGZ-UHFFFAOYSA-N 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- 150000003938 benzyl alcohols Chemical class 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 125000000392 cycloalkenyl group Chemical group 0.000 description 1
- 125000000753 cycloalkyl group Chemical group 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000007775 late Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000155 melt Substances 0.000 description 1
- 229910000474 mercury oxide Inorganic materials 0.000 description 1
- UKWHYYKOEPRTIC-UHFFFAOYSA-N mercury(ii) oxide Chemical compound [Hg]=O UKWHYYKOEPRTIC-UHFFFAOYSA-N 0.000 description 1
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000004899 motility Effects 0.000 description 1
- PSZYNBSKGUBXEH-UHFFFAOYSA-N naphthalene-1-sulfonic acid Chemical compound C1=CC=C2C(S(=O)(=O)O)=CC=CC2=C1 PSZYNBSKGUBXEH-UHFFFAOYSA-N 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 208000020016 psychiatric disease Diseases 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 230000035484 reaction time Effects 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229910001923 silver oxide Inorganic materials 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical compound NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- OKQKDCXVLPGWPO-UHFFFAOYSA-N sulfanylidenephosphane Chemical compound S=P OKQKDCXVLPGWPO-UHFFFAOYSA-N 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 229960005333 tetrabenazine Drugs 0.000 description 1
- 150000003672 ureas Chemical class 0.000 description 1
- 150000003673 urethanes Chemical class 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
<Desc/Clms Page number 1>
Verfahren zur Herstellung von neuen 3, 1-Benzothiazin-Derivaten und ihren Salzen
Die Erfindung betrifft ein Verfahren zur Herstellung neuer 3, 1-Benzothiazin-Derivate mit wertvollen pharmakologischen Eigenschaften.
EMI1.1
EMI1.2
EMI1.3
1-Benzothiazin-Derivateniedermolekulare Dialkylaminoalkylgruppe bedeutet, wobei die Dialkylaminogruppe auch, gegebenenfalls über ein Sauerstoff-oder Schwefelatom oder eine Methyl-oder Benzyl-iminogruppe, zum Ring geschlossen sein kann, Rl Wasserstoff oder Halogenatome, Methoxy-, Trifluormethyl- oder Nitrogruppen und R2 Alkyl-, Aralkyl- oder Arylreste bedeuten, wobei der Phenylring des Aralkyl- oder Arylrestes durch Halogenatome, Methoxy-, Trifluormethyl- oder Nitrogruppen substituiert sein kann, und deren Salzen mit anorganischen und organischen Säuren erhält,
wenn man Verbindungen der allgemeinen Formel
EMI1.4
<Desc/Clms Page number 2>
in der R, Rl und R2 die obige Bedeutung besitzen, mit Schwefelwasserstoff oder anorganischen Sulfiden, wie z. B. Phosphorpentasulfid, umsetzt und gegebenenfalls die erhaltenen basischen Verbindungen durch Behandlung mit anorganischen oder organischen Säuren in ihre Säureadditionssalze überführt.
Als Ausgangsstoffe der Formel II kommen beispielsweise in Frage :
2-Amino-4-phenyl-4H-3,1-benzoxazin,
2-Amino-4-phenyl-6-chlor-4H-3, 1-benzoxazin,
EMI2.1
-3, I-benzoxazin,2-Äthylamino-4-phenyl-7-chlor-4H-3, 1-benzoxazin,
2-Benzylamino-4-phenyl-6-methoxy-4H-3,1-benzoxazin,
2-Amino-5-methyl-4H-3,1-benzoxazin, 2-Äthylamino-4-methyl-4H-3, 1-benzoxazin,
2-Methylamino-4-äthyl-4H-3, 1-benzoxazin,
2-Äthylamino-4-methyl-6-chlor-4H-3, 1-benzoxazin, 2-Cyclohexylamino-4-methyl-6 -methoxy-4H -3, I-benzoxazin.
Die Verbindungen der allgemeinen Formel II kann man z. B. erhalten, wenn man Verbindungen der allgemeinen Formel
EMI2.2
in der Rl und R2 die obige Bedeutung besitzen und X ein Chlor- oder Bromatom, eine Hydroxyl-, Alkoxy- oder Alkanoyloxygruppe bedeutet, mit Isocyanaten der allgemeinen Formel 0=C=N-R, (IV) in der R die obige Bedeutung besitzt, oder entsprechenden Isocyanatbildnern, gegebenenfalls unter Zusatz von Säuren und/oder wasserabspaltenden Mitteln, umsetzt.
Für diese Umsetzung kommen als Verbindungen der allgemeinen Formel III beispielsweise 2-Aminobenzhydrole in Betracht. Hievon seien genannt : 2-Aminobenzhydrol, 2-Aminofluorbenzhydrole, 2-Aminochlorbenzhydrole, insbesondere 2-Amino-5-chlorbenzhydrol, 2-Aminobrombenzhydrole, 2-Amino-
EMI2.3
des die Aminogruppe tragenden Benzolringes und zwei in 2'-, 3'-, 4'-, 51- oder 61-Stellung des andern Benzolringes stehen können. Ferner können die den oben erwähnten Benzhydrolen entsprechenden nie-
EMI2.4
mit niederen aliphatischen Carbonsäuren, z. B. die Acetate oder Propionate der genannten Benzhydrole verwendet werden.
Die entsprechenden Halogenide, wie 2-Aminophenyl-phenylchlor- (bzw.-brom)- - methan sowie die in den Phenylresten entsprechend substituierten Verbindungen, können ebenfalls verwendet werden.
<Desc/Clms Page number 3>
Weiterhin kommen als Verbindungen der allgemeinen Formel in a-Alkyl-2-aminobenzylalkohole und IX-Aralkyl-2-aminobenzylalkohole in Betracht. Hievon seien genannt : a -Methyl-2-aminobenzylalkohol,
EMI3.1
wobei ebenfalls die im Anschluss an "2-Amino-" genannten Substituenten in 3-, 4-, 5-oder 6-Stellung des Benzolringes stehen können.
EMI3.2
genannten Benzylalkohole verwendet werden.
Die entsprechenden Halogenide, wie Methyl-2-aminophenylchlor- (bzw. -brom) -methan sowie die im Phenylrest entsprechend substituierten Verbindungen, können gleichfalls verwendet werden.
Die von den genannten basischen Verbindungen abgeleiteten Salze mit starken Säuren, wie Halogenwasserstoffsäuren, Schwefelsäure sowie Benzol- und Toluolsulfosäure, sind ebenfalls als Ausgangsstoffe geeignet.
Als Verbindungen der allgemeinen Formel IV können Isocyansäure und Isocyanate, wie Methyl-, Äthyl-, Propyl-, Isopropyl-, Butyl-, Isobutyl-, Hexyl-, Cyclohexyl-, Allyl-, Cyclohexenyl-, Phenyl-, Benzyl-, Dimethylaminopropylisocyanat verwendet werden, ferner kommen Isocyanatbildner (vgl.
Houben Weyl "Methoden der organischen Chemie"4. AufL Bd. 8, S. 119-127) wie die entsprechenden Carbaminsäurechloride und Urethane in Betracht.
Die Umsetzung der Verbindungen der allgemeinen Formel III mit den Verbindungen der allgemei-
EMI3.3
<Desc/Clms Page number 4>
Für die Umsetzung der Benzhydrylhalogenide der allgemeinen Formel III (X = Cl, Br) bzw. deren Säureadditionssalzen, mit den Verbindungen der allgemeinen Formel IV ist im allgemeinen die Gegenwart von Säuren oder wasserabspaltenden Mitteln zur Cyclisierung der intermediär gebildeten Harnstoffderivate nicht erforderlich. Diese Umsetzungen lassen sich vorzugsweise in der Schmelze oder durch Erhitzen in einem geeigneten Lösungsmittel durchführen.
Die Reaktionszeiten sind je nach Reaktionsfähigkeit der Komponenten und der gewählten Temperatur in weiten Grenzen variierbar. Zur Aufarbeitung können die meist als Salze anfallenden Reaktionsprodukte der allgemeinen Formel II, gegebenenfalls nach Einengen der Lösung, direkt isoliert und, falls gewünscht, durch anschliessende Behandlung mit Alkali in die freien Basen überführt werden.
Man kann auch das Reaktionsgemisch vor der Isolierung alkalisch stellen, wodurch sich die Verfahrensprodukte in üblicher Weise in Form der freien Basen isolieren lassen.
EMI4.1
vorzugsweise Phosphor (V) sulfid, oder deren Gemischen, wird bei Temperaturen von 50 bis 200 C, vorzugsweise 80 bis 160 C, gegebenenfalls unter Verwendung eines organischen Lösungsmittels, wie Pyridin, eines aromatischen Kohlenwasserstoffes, wie Benzol, Toluol oder Xylol, oder eines aliphatischen oder aromatischen Chlorkohlenwasserstoffes, wie Tetrachlorkohlenstoff, Tetrachloräthan oder Chlorbenzol durchgeführt. Je nach dem Siedepunkt des verwendeten Lösungsmittels sowie der notwendigen Reaktionstemperatur, insbesondere bei Verwendung von Schwefelwasserstoff, ist die Umsetzung gegebenenfalls unter Druck durchzuführen.
Die Endprodukte (Verfahrenserzeugnisse) können als basische Verbindungen mit Hilfe von anorganischen oder organischen Säuren in die entsprechenden Salze übergeführt werden. Als anorganische Säuren kommen beispielsweise in Betracht : Halogenwasserstoffsäuren, wie Chlorwasserstoffsäure und Bromwasserstoffsäure sowie Schwefelsäure, Phosphorsäure und Amidosulfonsäure. Als organische Säuren seien beispielsweise genannt : Essigsäure, Propionsäure, Milchsäure, Glykolsäure, Gluconsäure, Fumarsäure, Maleinsäure, Oxalsäure, Bernsteinsäure, Weinsäure, Benzoesäure, Salicylsäure, Citronensäure, Acetursäure, Oxyäthansulfonsäure und Äthylendiamintetraessigsäure, Embonsäure, Naphthalindisulfonsäure oder Toluolsulfonsäure.
Die Verfahrensprodukte besitzen bei zum Teil äusserst geringer Toxizität wertvolle pharmakologische Eigenschaften, insbesondere haben sie sowohl zentral depressive als auch anregende tranquillisierende, noradrenalinverstärkende und narkoseverlängernde und darüber hinaus z. B. auch analgetische und spasmolytische Wirksamkeit.
Die Verfahrensprodukte, wie z.B. 2-Athylamino-4-phenyl-6-chlor-4H-3,l-benzothiazin(LD 50 : > 6 g/kg bei Mäusen per os) sind hinsichtlich ihrer zentral depressiven Wirkung ähnlich strukturierten bekannten Verbindungen, beispielsweise dem 2-Äthylamino-4H-3, l-benzothiazin (LD50 : 800 mg/kg), deutlich überlegen. Sie besitzen ausserdem eine bemerkenswerte zentral depressive Spätwirkung.
Die zentral depressive Wirkung wurde durch Registrierung der spontanen und provozierten Motilität bei der Maus und im Somnolenz-Test (Nieschulz, O. et al., Arzneimittelforschung 6,651 [1956]) geprüft. Die Durchbrechung oder Aufhebung der durch 2-0xo-3-isobutyl-9, 10-dimethoxy-l, 2, 3, 4, 6, 7- - hexahydro-llbH-benzo- [ (x]-chinolizin (Tetrabenazin) ausgelöstem Katalepsie der Maus wurde in einer Modifikation der von Sulser et al. (Fed. Proc. 19, 268 [1960] und Ann. N. Y. Acad. Sci. 96, 279 [1962]) beschriebenen Versuchsanordnung geprüft. Die Prüfung auf noradrenalinpotenzierende Wirkung erfolgte am Katzenblutdruck.
Die Verfahrenserzeugnisse können als solche oder in Form entsprechender Salze gegebenenfalls unter Beimischung pharmazeutisch üblicher Trägerstoffe appliziert werden. Die pharmazeutischen Präparate können in Form von Tabletten, Dragées, Kapseln oder Suppositorien vorliegen, sie können auch in flüssiger Form als. Lösungen, Suspensionen oder Emulsionen verabreichtwerden. Als pharmazeutisch übliche Trägerstoffe kommen solche Stoffe in Frage, die nicht mit den Verfahrensprodukten reagieren, wie z. B. Wasser, Gelatine, Lactose, Stärke, Magnesiumstearat, Talkum, pflanzliche Öle, Polyalkylenglykole u. ähnl. Sie können sterilisiert und/oder mit Stabilisatoren versetzt werden. Die pharmazeutischen Präparate können auch weitere therapeutisch wertvolle Substanzen enthalten.
Die Verfahrenserzeugnisse dienen zur Behandlung von psychischen Erkrankungen, z. B. Depressionen, Psychoneurosen, Verstimmungen und Angstzuständen neurotischer und psychotischer Genese. Die
EMI4.2
<Desc/Clms Page number 5>
bad erhitzt und anschliessend über Nacht bei Raumtemperatur aufbewahrt. Der entstandene Kristallbrei wird zur Entfernung von überschüssigem Senföl mit 75 ml Benzol ausgekocht. Man erhält so 43 g (89'/0 d. Th.) N-Äthyl-N'-E4-chlor-2- ( < x-hydroxybenzyl) ] -phenyl-thioharnstoff als farblose Kristalle vom Schmelzpunkt 147 bis 1480, der auch beim Umkristallisieren aus Essigester/Petroläther konstant bleibt. b) 18 g des nach a) hergestellten Thioharnstoffes werden mit 23 g Silberoxyd in 250 ml Äthanol 45 min unter Rühren am Rückfluss gekocht.
Man filtriert heiss und dampft das Lösungsmittel im Vakuum ab. Durch mehrmaliges Extrahieren des öligen Rückstandes mit heissem Petroläther lassen sich 11 g (77go d. Th.) 2-Äthylamino-4-phenyl-6-chlor-4H-3, 1-benzoxazin vom Schmelzpunkt 124 bis 1250 gewinnen. c) 14 g 2-Äthylamino-4-phenyl-6-chlor-4H-3, l-benzoxazin in 100 ml Pyridin werden mit der doppelten Gewichtsmenge Phosphorpentasulfid 2 h unter Rühren am Rückfluss gekocht. Nach Erkalten fügt man 500 ml verdünnte Natronlauge zu und rührt 1 h bei Zimmertemperatur weiter. Anschliessend wird abgesaugt, der farblose Niederschlag mit Wasser gründlich gewaschen, getrocknet und aus Benzol/Petroläther umkristallisiert.
Man erhält auf diese Weise 11 g (73go d. Th.) 2-Äthylamino-4-phe- nyl-6-chlor-4H-3, 1-benzothiazin als farblose Kristalle vom Schmelzpunkt 118 bis 1200. beispiel2 :2-Äthylamino-4-methyl-4H-3,1-benzothiazin. a) 13, 7 g a-Methyl-2-aminobenzylalkohol werden zusammen mit 13,0 g Äthylsenföl 10 min auf 90 bis 1000 erhitzt. Das beim Erkalten langsam kristallisierende Reaktionsgemisch wird mit Petroläther verrieben und der kristalline Niederschlag durch Absaugen isoliert.
Durch Umkristallisieren aus Benzol erhält man 20, 6 g (92% d. Th.) N-Äthyl-N'-[2-(α-hydroxyäthyl)]-phenyl-thioharnstoff als farblose Kristalle vom Schmelzpunkt 108 bis 1100. b) 22, 4 g des nach a) erhaltenen Thioharnstoffes werden mit 40 g Quecksilberoxyd in 200 ml Äthanol 30 min unter Rühren am Rückfluss gekocht. Das Reaktionsgemisch wird heiss filtriert und das Lösungsmittel im Vakuum abgedampft. Hiebei hinterbleibt 2-Äthylamino-4-methyl-4H-3, l-benzoxazinals farbloses Öl, welches bald kristallin erstarrt.
Nach Umkristallisieren aus Petroläther erhält man 16, 5 g (87go d. Th.) farblose Kristalle vom Schmelzpunkt 66 bis 680. c) 19 g 2-Äthylamino-4-methyl-4H-3, 1-benzoxazin werden zusammen mit 40 g Phosphorpentasulfid in 200 ml Toluol 3 h unter Rühren am Rückfluss erhitzt. Nach dem Erkalten dekantiert man ab und entfernt das Lösungsmittel im Vakuum. Der hinterbleibende Rückstand liefert nach Umkristallisieren aus Benzol/Petroläther bzw. Äthanol/Wasser 13, 5 g (65duo d. Th.) 2-Äthylamino-4-methyl-4H-3, 1- - benzothiazin vom Schmelzpunkt 91 bis 920.
PATENTANSPRÜCHE :
1. Verfahren zur Herstellung von neuen 3, l-Benzothiazin-Derivaten der allgemeinen Formel
EMI5.1
in der R Wasserstoff, eine Alkyl-, Cycloalkyl-, Alkenyl-, Cycloalkenyl-, Aryl-, Aralkyl- oder eine niedermolekulare Dialkylaminoalkylgruppe bedeutet, wobei die Dialkylaminogruppe auch, gegebenenfalls über ein Sauerstoff-oder Schwefelatom oder eine Methyl- oder Benzyl-iminogruppe, zum Ring geschlossen sein kann, Rl Wasserstoff oder Halogenatome, Methoxy-, Trifluormethyl- oder Nitrogruppen und R2 einen Phenylrest bedeutet, der durch Halogenatome sowie Methoxy-, Trifluormethyl- oder Ni-
**WARNUNG** Ende DESC Feld kannt Anfang CLMS uberlappen**.
<Desc / Clms Page number 1>
Process for the preparation of new 3, 1-benzothiazine derivatives and their salts
The invention relates to a process for the preparation of new 3,1-benzothiazine derivatives with valuable pharmacological properties.
EMI1.1
EMI1.2
EMI1.3
1-Benzothiazine derivatives denotes low molecular weight dialkylaminoalkyl groups, where the dialkylamino group can also be closed to form a ring, optionally via an oxygen or sulfur atom or a methyl or benzylimino group, R1 hydrogen or halogen atoms, methoxy, trifluoromethyl or nitro groups and R2 alkyl -, aralkyl or aryl radicals, where the phenyl ring of the aralkyl or aryl radical can be substituted by halogen atoms, methoxy, trifluoromethyl or nitro groups, and contains their salts with inorganic and organic acids,
when considering compounds of the general formula
EMI1.4
<Desc / Clms Page number 2>
in which R, Rl and R2 have the above meaning, with hydrogen sulfide or inorganic sulfides, such as. B. phosphorus pentasulphide, and optionally converted the basic compounds obtained into their acid addition salts by treatment with inorganic or organic acids.
Possible starting materials of the formula II are, for example:
2-amino-4-phenyl-4H-3,1-benzoxazine,
2-amino-4-phenyl-6-chloro-4H-3, 1-benzoxazine,
EMI2.1
-3, I-benzoxazine, 2-ethylamino-4-phenyl-7-chloro-4H-3, 1-benzoxazine,
2-benzylamino-4-phenyl-6-methoxy-4H-3,1-benzoxazine,
2-Amino-5-methyl-4H-3,1-benzoxazine, 2-ethylamino-4-methyl-4H-3, 1-benzoxazine,
2-methylamino-4-ethyl-4H-3, 1-benzoxazine,
2-Ethylamino-4-methyl-6-chloro-4H-3, 1-benzoxazine, 2-cyclohexylamino-4-methyl-6-methoxy-4H -3, I-benzoxazine.
The compounds of general formula II can be, for. B. obtained when using compounds of the general formula
EMI2.2
in which Rl and R2 have the above meaning and X is a chlorine or bromine atom, a hydroxyl, alkoxy or alkanoyloxy group, with isocyanates of the general formula 0 = C = NR, (IV) in which R has the above meaning, or appropriate isocyanate formers, optionally with the addition of acids and / or dehydrating agents.
Compounds of the general formula III which can be used for this reaction are, for example, 2-aminobenzhydrols. Of these, there may be mentioned: 2-aminobenzhydrol, 2-aminofluorobenzhydroles, 2-aminochlorobenzhydroles, in particular 2-amino-5-chlorobenzhydrol, 2-aminobromobenzhydrols, 2-amino
EMI2.3
of the benzene ring bearing the amino group and two in the 2'-, 3'-, 4'-, 51- or 61-position of the other benzene ring. Furthermore, the lower levels corresponding to the above-mentioned benzhydrols
EMI2.4
with lower aliphatic carboxylic acids, e.g. B. the acetates or propionates of the benzhydrols mentioned can be used.
The corresponding halides, such as 2-aminophenyl-phenylchloro- (or -bromo) - methane and the compounds correspondingly substituted in the phenyl radicals, can also be used.
<Desc / Clms Page number 3>
Further suitable compounds of the general formula are α-alkyl-2-aminobenzyl alcohols and IX-aralkyl-2-aminobenzyl alcohols. Of these, the following may be mentioned: a -Methyl-2-aminobenzyl alcohol,
EMI3.1
where the substituents mentioned after "2-amino-" can likewise be in the 3-, 4-, 5- or 6-position of the benzene ring.
EMI3.2
mentioned benzyl alcohols are used.
The corresponding halides, such as methyl-2-aminophenylchloro- (or -bromo) -methane and the compounds correspondingly substituted in the phenyl radical, can also be used.
The salts with strong acids, such as hydrohalic acids, sulfuric acid and benzene and toluenesulphonic acid, derived from the basic compounds mentioned, are also suitable as starting materials.
Isocyanic acid and isocyanates, such as methyl, ethyl, propyl, isopropyl, butyl, isobutyl, hexyl, cyclohexyl, allyl, cyclohexenyl, phenyl, benzyl, dimethylaminopropyl isocyanate, can be used as compounds of the general formula IV isocyanate formers (cf.
Houben Weyl "Methods of Organic Chemistry" 4. AufL Vol. 8, pp. 119-127) as well as the corresponding carbamic acid chlorides and urethanes.
The implementation of the compounds of the general formula III with the compounds of the general
EMI3.3
<Desc / Clms Page number 4>
The reaction of the benzhydryl halides of the general formula III (X = Cl, Br) or their acid addition salts with the compounds of the general formula IV generally does not require the presence of acids or dehydrating agents for cyclizing the urea derivatives formed as intermediates. These reactions can preferably be carried out in the melt or by heating in a suitable solvent.
The reaction times can be varied within wide limits depending on the reactivity of the components and the selected temperature. For work-up, the reaction products of the general formula II, which are usually obtained as salts, can be isolated directly, if appropriate after concentration of the solution, and, if desired, converted into the free bases by subsequent treatment with alkali.
The reaction mixture can also be made alkaline before isolation, whereby the process products can be isolated in the customary manner in the form of the free bases.
EMI4.1
preferably phosphorus (V) sulfide, or mixtures thereof, is at temperatures of 50 to 200 ° C., preferably 80 to 160 ° C., optionally using an organic solvent such as pyridine, an aromatic hydrocarbon such as benzene, toluene or xylene, or an aliphatic solvent or aromatic chlorinated hydrocarbons such as carbon tetrachloride, tetrachloroethane or chlorobenzene. Depending on the boiling point of the solvent used and the necessary reaction temperature, especially when using hydrogen sulfide, the reaction may be carried out under pressure.
The end products (process products) can be converted into the corresponding salts as basic compounds with the aid of inorganic or organic acids. Examples of inorganic acids are: hydrohalic acids, such as hydrochloric acid and hydrobromic acid, and also sulfuric acid, phosphoric acid and amidosulfonic acid. Examples of organic acids are: acetic acid, propionic acid, lactic acid, glycolic acid, gluconic acid, fumaric acid, maleic acid, oxalic acid, succinic acid, tartaric acid, benzoic acid, salicylic acid, citric acid, aceturic acid, oxyethanesulphonic acid and ethylenediaminetetraacetic acid or toluenesulphonic acid, naphthalenesulphonic acid.
The products of the process have valuable pharmacological properties with extremely low toxicity in some cases; B. also analgesic and spasmolytic effectiveness.
The process products, such as e.g. 2-Ethylamino-4-phenyl-6-chloro-4H-3, l-benzothiazine (LD 50:> 6 g / kg in mice per os) are known compounds with a similar structure in terms of their central depressive effect, for example the 2-ethylamino- 4H-3, l-benzothiazine (LD50: 800 mg / kg), clearly superior. They also have a remarkable central depressive late effect.
The central depressive effect was examined by registering the spontaneous and provoked motility in the mouse and in the somnolence test (Nieschulz, O. et al., Arzneimittelforschung 6,651 [1956]). The breakthrough or abolition of the catalepsy caused by 2-0xo-3-isobutyl-9, 10-dimethoxy-1,2, 3, 4, 6, 7- hexahydro-llbH-benzo [(x] -quinolizine (tetrabenazine)) The mouse was tested in a modification of the test arrangement described by Sulser et al. (Fed. Proc. 19, 268 [1960] and Ann. NY Acad. Sci. 96, 279 [1962]) .The test for noradrenaline-potentiating effects was carried out on the cat's blood pressure .
The products of the process can be applied as such or in the form of corresponding salts, optionally with admixture of customary pharmaceutically acceptable carriers. The pharmaceutical preparations can be in the form of tablets, dragees, capsules or suppositories; they can also be in liquid form as. Solutions, suspensions or emulsions can be administered. The usual pharmaceutically acceptable carriers are those substances that do not react with the products of the process, such as. B. water, gelatin, lactose, starch, magnesium stearate, talc, vegetable oils, polyalkylene glycols and. similar They can be sterilized and / or treated with stabilizers. The pharmaceutical preparations can also contain other therapeutically valuable substances.
The process products are used to treat mental illnesses, e.g. B. Depression, psychoneuroses, moods and anxiety states of neurotic and psychotic origin. The
EMI4.2
<Desc / Clms Page number 5>
heated bath and then stored overnight at room temperature. The resulting crystal paste is boiled with 75 ml of benzene to remove excess mustard oil. 43 g (89 '/ 0 of theory) of N-ethyl-N'-E4-chloro-2- (<x-hydroxybenzyl)] phenylthiourea are thus obtained as colorless crystals with a melting point of 147 to 1480, which is also the case remains constant when recrystallized from ethyl acetate / petroleum ether. b) 18 g of the thiourea prepared according to a) are refluxed with 23 g of silver oxide in 250 ml of ethanol for 45 minutes while stirring.
It is filtered hot and the solvent is evaporated off in vacuo. By repeatedly extracting the oily residue with hot petroleum ether, 11 g (77% of theory) of 2-ethylamino-4-phenyl-6-chloro-4H-3, 1-benzoxazine with a melting point of 124 to 1250 can be obtained. c) 14 g of 2-ethylamino-4-phenyl-6-chloro-4H-3, l-benzoxazine in 100 ml of pyridine are refluxed with twice the weight of phosphorus pentasulfide for 2 hours while stirring. After cooling, 500 ml of dilute sodium hydroxide solution are added and the mixture is stirred for a further 1 h at room temperature. It is then filtered off with suction, the colorless precipitate is washed thoroughly with water, dried and recrystallized from benzene / petroleum ether.
In this way 11 g (73% of theory) of 2-ethylamino-4-phenyl-6-chloro-4H-3,1-benzothiazine are obtained as colorless crystals with a melting point of 118 to 1200. Example 2: 2-Ethylamino- 4-methyl-4H-3,1-benzothiazine. a) 13.7 g of a-methyl-2-aminobenzyl alcohol are heated to 90 to 1000 for 10 minutes together with 13.0 g of ethyl mustard oil. The reaction mixture, which slowly crystallizes on cooling, is triturated with petroleum ether and the crystalline precipitate is isolated by suction.
Recrystallization from benzene gives 20.6 g (92% of theory) of N-ethyl-N '- [2 - (α-hydroxyethyl)] - phenylthiourea as colorless crystals with a melting point of 108 to 1100. b) 22.4 g of the thiourea obtained according to a) are refluxed with 40 g of mercury oxide in 200 ml of ethanol for 30 minutes while stirring. The reaction mixture is filtered hot and the solvent is evaporated off in vacuo. This leaves 2-ethylamino-4-methyl-4H-3, l-benzoxazine as a colorless oil, which soon solidifies in crystalline form.
After recrystallization from petroleum ether, 16.5 g (87% of theory) of colorless crystals with a melting point of 66 to 680 are obtained. C) 19 g of 2-ethylamino-4-methyl-4H-3, 1-benzoxazine are added together with 40 g of phosphorus pentasulfide heated under reflux in 200 ml of toluene for 3 h with stirring. After cooling, it is decanted and the solvent is removed in vacuo. After recrystallization from benzene / petroleum ether or ethanol / water, the remaining residue yields 13.5 g (65% of the theory) of 2-ethylamino-4-methyl-4H-3, 1- benzothiazine with a melting point of 91 to 920.
PATENT CLAIMS:
1. Process for the preparation of new 3, l-benzothiazine derivatives of the general formula
EMI5.1
in which R denotes hydrogen, an alkyl, cycloalkyl, alkenyl, cycloalkenyl, aryl, aralkyl or a low molecular weight dialkylaminoalkyl group, the dialkylamino group also optionally via an oxygen or sulfur atom or a methyl or benzylimino group, can be closed to the ring, Rl is hydrogen or halogen atoms, methoxy, trifluoromethyl or nitro groups and R2 is a phenyl radical, which is represented by halogen atoms and methoxy, trifluoromethyl or Ni
** WARNING ** End of DESC field may overlap beginning of CLMS **.
Claims (1)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DEF0048739 | 1966-03-23 | ||
| DEF0048738 | 1966-03-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AT268323B true AT268323B (en) | 1969-02-10 |
Family
ID=25977107
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT625267A AT268323B (en) | 1966-03-23 | 1966-06-01 | Process for the preparation of new 3,1-benzothiazine derivatives and their salts |
Country Status (1)
| Country | Link |
|---|---|
| AT (1) | AT268323B (en) |
-
1966
- 1966-06-01 AT AT625267A patent/AT268323B/en active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CH651300A5 (en) | HETEROCYCLICALLY SUBSTITUTED AMINOPROPENNITRILE. | |
| DE2818947C2 (en) | ||
| DE1670772A1 (en) | Process for the preparation of benzoxazine derivatives | |
| DE2655009A1 (en) | ISOXAZOLE DERIVATIVES, THE PROCESS FOR THEIR MANUFACTURING AND MEANS CONTAINING THESE COMPOUNDS | |
| DE1670679C3 (en) | 4H-3,1-Benzoxazine derivatives and processes for their preparation | |
| CH632994A5 (en) | Process for preparing guanidine derivatives | |
| DE1122541B (en) | Process for the production of sulfamyl-anthranilic acids | |
| AT268323B (en) | Process for the preparation of new 3,1-benzothiazine derivatives and their salts | |
| DE1246722B (en) | Process for the production of urea derivatives | |
| DE2713586A1 (en) | NEW ORGANIC COMPOUNDS, METHODS OF MANUFACTURING AND USING THEM | |
| CH633545A5 (en) | METHOD FOR PRODUCING 2,1,3-thiadiazin-4-ON-2,2-DIOXIDE DERIVATIVES. | |
| DE1120456B (en) | Process for the preparation of new 4-oxo-3, 4-dihydro-2, 1, 3-benzothiadiazine-2, 2-dioxydes | |
| AT268300B (en) | Process for the preparation of new 3,1-benzothiazine derivatives and their salts | |
| AT268321B (en) | Process for the preparation of new heterocyclic compounds and their salts | |
| DE1246742B (en) | Process for the production of new phenothiazines | |
| DE1695092A1 (en) | Process for the preparation of sulfonamides | |
| DE1038047B (en) | Process for the preparation of N-aminoalkylated iminodibenzyls and their salts | |
| CH492729A (en) | (A) 3,1-Benzothiazines and 3,1-benzoxazines of gen. formula (I), where A = O or S R = H, alkyl, cycloalkyl, alkenyl, cycloalkenyl aryl, aralkyl, or | |
| AT349484B (en) | PROCESS FOR PRODUCING NEW THIENOTHIAZINE DERIVATIVES | |
| AT332423B (en) | PROCESS FOR MANUFACTURING NEW PYRIDYLTHIOURA | |
| AT223189B (en) | Process for the preparation of new aryloxyacetic acid amides | |
| AT268322B (en) | Process for the preparation of new benzoxazine derivatives and their salts | |
| AT219613B (en) | Process for the preparation of new N-heterocyclic compounds and their salts | |
| AT343119B (en) | PROCESS FOR THE PREPARATION OF NEW 10H-THIENO (3,2-C) (1) BENZAZEPINE DERIVATIVES AND THEIR ACID ADDITIONAL SALTS | |
| AT318631B (en) | Process for the preparation of new 1,5-benzodiazepines |